Risk factors for developing GVHD after orthotopic liver and intestinal transplantation
| Orthotopic liver4,10,25-30 . | Intestinal and MV5,31,32 . |
|---|---|
| Donor-recipient HLA matching | Multivisceral or liver-included graft |
| Recipient age >40 y | Larger graft volume |
| Donor-recipient age difference >20 y | Transplant for MIAI |
| Recipient glucose intolerance | Retransplantation |
| Recipient infection with CMV or HSV | |
| Transplant for AALD, HCC, or AILD | |
| Liver allograft with ≥6% steatosis | |
| Donor death from CVA | |
| Donor-recipient race mismatching | |
| Use of induction immunosuppression |
| Orthotopic liver4,10,25-30 . | Intestinal and MV5,31,32 . |
|---|---|
| Donor-recipient HLA matching | Multivisceral or liver-included graft |
| Recipient age >40 y | Larger graft volume |
| Donor-recipient age difference >20 y | Transplant for MIAI |
| Recipient glucose intolerance | Retransplantation |
| Recipient infection with CMV or HSV | |
| Transplant for AALD, HCC, or AILD | |
| Liver allograft with ≥6% steatosis | |
| Donor death from CVA | |
| Donor-recipient race mismatching | |
| Use of induction immunosuppression |
AALD, alcohol-associated liver disease; AILD, autoimmune liver disease; CVA, cerebrovascular accident; HCC, hepatocellular carcinoma; MIAI, multiple intestinal atresia and immunodeficiency; MV, multivisceral transplantation.